FDA grants fast track designation to GEN-1 for advanced ovarian cancer

400020

February 23, 2021

1 min read

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA granted fast track designation to GEN-1 for treatment of advanced ovarian cancer, according to the agent’s manufacturer.

GEN-1 (Celsion) is a DNA-mediated interleukin-12 immunotherapy.

Source: Adobe Stock.

“Fast track designation is an important step in developing GEN-1 for advanced ovarian cancer,” Michael H. Tardugno, Celsion’s chairman, president and CEO, said in a company-issued press release. “Presuming the encouraging data we are generating in early clinical studies continues, this designation supports an expedited path to market. … We are optimistic that GEN-1 represents a game-changer for women with advanced ovarian cancer who have limited treatment options.”

The phase 2 OVATION 2 study is evaluating the addition of GEN-1 to standard neoadjuvant chemotherapy for women with newly diagnosed stage III/stage IV ovarian cancer…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close